Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Follow up approaches in thyroid cancer: a risk adapted paradigm.

Tuttle RM, Leboeuf R.

Endocrinol Metab Clin North Am. 2008 Jun;37(2):419-35, ix-x. doi: 10.1016/j.ecl.2008.02.008. Review.

PMID:
18502335
2.

Medical management of thyroid cancer: a risk adapted approach.

Tuttle RM, Leboeuf R, Shaha AR.

J Surg Oncol. 2008 Jun 15;97(8):712-6. doi: 10.1002/jso.21010. Review.

PMID:
18493922
3.

Contemporary post surgical management of differentiated thyroid carcinoma.

Tala H, Tuttle RM.

Clin Oncol (R Coll Radiol). 2010 Aug;22(6):419-29. doi: 10.1016/j.clon.2010.04.005. Epub 2010 Jun 1. Review.

PMID:
20605708
4.

Risk-adapted management of thyroid cancer.

Tuttle RM.

Endocr Pract. 2008 Sep;14(6):764-74. Review.

PMID:
18996800
5.

High rate of persistent/recurrent disease among patients with differentiated thyroid cancer in Saudi Arabia: factors affecting nonremission.

Raef H, Alfadhli E, Al-Hajjaj A, Malabu UH, Al-Sobhi S, Rifai A, Al Nuaim A.

Ann Saudi Med. 2008 Jul-Aug;28(4):277-81.

PMID:
18596397
6.

Endoluminal resection for sessile neoplasia in the GI tract is associated with a low recurrence rate and a high 5-year survival rate.

Wang AY, Ahmad NA, Zaidman JS, Brensinger CM, Lewis JD, Long WB, Kochman ML, Ginsberg GG.

Gastrointest Endosc. 2008 Jul;68(1):160-9. doi: 10.1016/j.gie.2008.03.002.

PMID:
18577483
7.

High recurrent rate of multicentric papillary thyroid carcinoma.

Lin JD, Chao TC, Hsueh C, Kuo SF.

Ann Surg Oncol. 2009 Sep;16(9):2609-16. doi: 10.1245/s10434-009-0565-7. Epub 2009 Jun 16.

PMID:
19533244
8.

Pediatric differentiated thyroid carcinoma in stage I: risk factor analysis for disease free survival.

Wada N, Sugino K, Mimura T, Nagahama M, Kitagawa W, Shibuya H, Ohkuwa K, Nakayama H, Hirakawa S, Rino Y, Masuda M, Ito K.

BMC Cancer. 2009 Sep 1;9:306. doi: 10.1186/1471-2407-9-306.

9.

High risk NSGCT: case for surveillance.

Kakiashvili DM, Zuniga A, Jewett MA.

World J Urol. 2009 Aug;27(4):441-7. doi: 10.1007/s00345-009-0453-6. Epub 2009 Jul 16.

PMID:
19609532
10.

Evidence-based review of treatment and follow up of pediatric patients with differentiated thyroid carcinoma.

Rachmiel M, Charron M, Gupta A, Hamilton J, Wherrett D, Forte V, Daneman D.

J Pediatr Endocrinol Metab. 2006 Dec;19(12):1377-93. Review.

PMID:
17252690
11.

Therapeutic outcomes of papillary thyroid carcinomas with tumors more advanced than T1N0M0.

Lin JD, Lin KJ, Chao TC, Hseuh C, Tsang NM.

Radiother Oncol. 2008 Oct;89(1):97-104. doi: 10.1016/j.radonc.2008.05.011. Epub 2008 Jun 3.

PMID:
18534700
12.

Recombinant human thyroid-stimulating hormone (Thyrogen) in thyroid cancer follow up: experience at a single institution.

Wong R, Topliss DJ, Bach LA, Hamblin PS, Kalff V, Long F, Stockigt JR.

Intern Med J. 2009 Mar;39(3):156-63. doi: 10.1111/j.1445-5994.2008.01735.x.

PMID:
19383064
13.

Postoperative management of thyroid carcinoma.

Manzone TA, Dam HQ, Intenzo CM, Sagar VV, Schneider CJ, Seshadri P.

Surg Oncol Clin N Am. 2008 Jan;17(1):197-218, x. doi: 10.1016/j.soc.2007.10.003. Review.

PMID:
18177807
14.

Changing paradigms in breast cancer management: introducing molecular genetics into the treatment algorithm.

Rayhanabad JA, Difronzo LA, Haigh PI, Romero L.

Am Surg. 2008 Oct;74(10):887-90.

PMID:
18942607
15.

Progress in thyroid cancer.

Kaplan MM.

Endocrinol Metab Clin North Am. 1990 Sep;19(3):469-78. Review.

PMID:
2261903
16.

Factors related to recurrence after pathological complete response to postoperative chemotherapy in patients with epithelial ovarian cancer.

Karagol H, Saip P, Eralp Y, Topuz S, Berkman S, Ilhan R, Topuz E.

Tumori. 2009 Mar-Apr;95(2):207-11.

17.

Medical management of persistent or recurrent differentiated thyroid carcinoma.

Jun JY, Manni A.

Otolaryngol Clin North Am. 2008 Dec;41(6):1241-60, xi-xii. doi: 10.1016/j.otc.2008.05.005. Review.

PMID:
19040983
18.

Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study.

Wahlin A, Billström R, Björ O, Ahlgren T, Hedenus M, Höglund M, Lindmark A, Markevärn B, Nilsson B, Sallerfors B, Brune M.

Eur J Haematol. 2009 Aug;83(2):99-107. doi: 10.1111/j.1600-0609.2009.01256.x. Epub 2009 Apr 6.

PMID:
19385987
19.
20.

Patterns of relapse following radiotherapy for differentiated thyroid cancer: implication for target volume delineation.

Azrif M, Slevin NJ, Sykes AJ, Swindell R, Yap BK.

Radiother Oncol. 2008 Oct;89(1):105-13. doi: 10.1016/j.radonc.2008.05.023. Epub 2008 Jun 23.

PMID:
18579244

Supplemental Content

Support Center